6-甲氧基-2,3,4,5-四氢-1H-苯并[b]氮杂卓盐酸盐 | 604004-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 6-甲氧基-2,3,4,5-四氢-1H-苯并[b]氮杂卓盐酸盐
• 英文名称: 6-methoxy-2,3,4,5-tetrahydro-1H-1-benzazepine
• 英文别名: 6-methoxy-2,3,4,5-tetrahydro-1H-benzo[b]azepine
• CAS: 604004-23-1
• 化学式: C₁₁H₁₅NO
• mdl: MFCD09026491
• 分子量: 177.246
• InChiKey: DOBAVTLLNQMEJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-甲氧基-2,3,4,5-四氢-1H-苯并[b]氮杂卓盐酸盐 在 盐酸羟胺 、 potassium carbonate 、 potassium hydroxide 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 7.0h， 生成 N-hydroxy-4-((6-methoxy-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methyl)benzamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113383
• 作为产物：
  描述：

  5-methoxy-3,4-dihydro-2H-naphthalen-1-one oxime 在 二异丁基氢化铝 、 sodium fluoride 作用下， 以 正己烷 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 以60%的产率得到6-甲氧基-2,3,4,5-四氢-1H-苯并[b]氮杂卓盐酸盐
  参考文献：
  名称：

  Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113383

文献信息

• Compounds
  申请人：Szewczyk Ryszard Jerzy

  公开号：US20060003991A1

  公开（公告）日：2006-01-05

  The present invention provides a compound of formula I comprising: a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

  本发明提供了一种包括公式I的化合物，其中包括：药用可接受的盐、溶剂化合物或其生理功能衍生物。
• [EN] 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS<br/>[FR] 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES SUBSTITUES EN POSITION 6 EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
  申请人：LILLY CO ELI

  公开号：WO2005082859A1

  公开（公告）日：2005-09-09

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: I where: R6 is -C=C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.

  本发明提供了公式I中的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症/强迫性障碍、抑郁症和焦虑症：I其中：R6为-C=C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。
• Fused pyramidine derivative and use thereof
  申请人：Hamamura Kazumasa

  公开号：US20070010537A1

  公开（公告）日：2007-01-11

  There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R 1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring A a is a 6-membered aromatic ring which may be further substituted, ring B a is a homocyclic or heterocyclic ring which may be further substituted, W a is an oxygen atom or a sulfur atom, X a1 and X a2 , which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or X a1 and X a2 together may form an oxygen atom, a sulfur atom or NR 3a (wherein R 3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Y a is C 1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

  提供了一种融合嘧啶化合物，具有抗促黄体激素释放激素的拮抗活性，以及含有该化合物的药物。一种促黄体激素释放激素拮抗剂，包含以下式子所代表的化合物：其中，R1a是一个可以被取代的碳氢基团或氢原子，环A是一个可以进一步取代的6元芳香环，环B是一个可以进一步取代的同环或异环，Wa是一个氧原子或硫原子，Xa1和Xa2，可能相同或不同，是每个可以被取代的碳氢基团或杂环基团，或Xa1和Xa2在一起可以形成氧原子、硫原子或NR3a（其中R3a是一个可以被取代的碳氢基团或氢原子），而Y是C1-6烷基，可以被取代或成为键，或其盐或前药。
• FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1657238A1

  公开（公告）日：2006-05-17

  There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring Aa is a 6-membered aromatic ring which may be further substituted, ring Ba is a homocyclic or heterocyclic ring which may be further substituted, Wa is an oxygen atom or a sulfur atom, Xa1 and Xa2, which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or Xa1 and Xa2 together may form an oxygen atom, a sulfur atom or NR3a (wherein R3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Ya is C1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

  提供了一种对黄体生成素释放激素具有拮抗活性的融合嘧啶化合物，以及一种含有该化合物的药物。一种黄体生成素释放激素拮抗剂含有由式表示的化合物： 其中 R1a 是可被取代的烃基或氢原子、 环 Aa 是可被进一步取代的 6 元芳香环、 环 Ba 是可被进一步取代的同环或杂环、 Wa 是氧原子或硫原子、 Xa1 和 Xa2（可以相同或不同）各自是氢原子、可被取代的烃基或可被取代的杂环基，或 Xa1 和 Xa2 可共同形成氧原子、硫原子或 NR3a（其中 R3a 是可被取代的烃基或氢原子），以及 Ya 是可被取代的 C1-6 亚烷基或键，或其盐或原药。
• Dynamic and Static Conformational Analysis of Acylated Tetrahydrobenzazepines
  作者：Alfred Hassner、Boaz Amit、Vered Marks、Hugo E. Gottlieb

  DOI：10.1021/jo0340105

  日期：2003.9.1

  A detailed high-field NMR analysis of several acylated tetrahydrobenzazepines, supported by molecular mechanics calculations, indicates that the heterocyclic ring in these compounds exists in a chair conformation, with the carbonyl oriented anti to the aryl moiety in the dominant rotamer. Surprisingly, ring methylenes are typically diastereotopic at room temperature, as the barriers for the process of enantiomerization of the seven-membered ring are much higher than expected. It is shown that ring inversion is correlated (but not concerted) with rotation of the amide moiety, as the carbonyl is forced out of conjugation with the nitrogen in the transition state.